Shares of Forte Biosciences stock opened at $1.12 on Thursday. Forte Biosciences has a twelve month low of $1.03 and a twelve month high of $7.26. The business’s fifty day moving average price is $1.36 and its 200 day moving average price is $1.82.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in Forte Biosciences by 5.9% in the fourth quarter. BlackRock Inc. now owns 817,063 shares of the company’s stock valued at $1,748,000 after purchasing an additional 45,337 shares during the period. State Street Corp raised its position in Forte Biosciences by 21.0% in the fourth quarter. State Street Corp now owns 561,348 shares of the company’s stock valued at $1,201,000 after purchasing an additional 97,456 shares during the period. Geode Capital Management LLC raised its position in Forte Biosciences by 152.0% in the fourth quarter. Geode Capital Management LLC now owns 255,471 shares of the company’s stock valued at $546,000 after purchasing an additional 154,086 shares during the period. Renaissance Technologies LLC purchased a new position in Forte Biosciences in the first quarter valued at about $277,000. Finally, Parametric Portfolio Associates LLC raised its position in Forte Biosciences by 57.2% in the fourth quarter. Parametric Portfolio Associates LLC now owns 174,724 shares of the company’s stock valued at $374,000 after purchasing an additional 63,582 shares during the period. 37.11% of the stock is currently owned by institutional investors.
Forte Biosciences, Inc operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
- Get a free copy of the StockNews.com research report on Forte Biosciences (FBRX)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.